ARTbio: manufacturing strategy to lead on lead-212 radiotherapies

ARTbio is betting cancer radiotherapies based on lead-212 will have an efficacy advantage over more commonly used radioisotopes, and is developing manufacturing strategies to solve the logistical hurdles that are the flip side of its greater potency.

Launched Wednesday with a $23 million seed round, clinical-stage ARTbio Inc. is part of the growing wave of companies developing targeted radiotherapies that emit alpha particles, which deliver more tumor-killing energy over a shorter radius than beta-emitting compounds such as Pluvicto, the prostate cancer radiotherapy from Novartis AG (SIX:NOVN; NYSE:NVS)...